No.4
会社はしきりとファーストインクラスになる可能性のある薬だとは書いてるけど・・・
アトピーと円形脱毛症か。
Our portfolio is led by eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor that has the potential to improve upon current biologics used to treat allergic disease.
We are also developing farudodstat, a potent oral inhibitor of the enzyme DHODH, as a potential first-in-class treatment for alopecia areata.
返信
投資の参考になりましたか？
